Ajanta Pharma looks to expand ops in high-growth Asian, African geographies

As a part of its development plans, Ajanta Pharma is trying to improve its presence throughout choose geographies with excessive development potential in Asia and Africa. In its Annual Report for 2022-23, the Mumbai-based drug maker acknowledged that it intends to depend on its strengths to develop quicker in international locations the place it has a presence with its vary of branded generics.

“As we obtain formidable positions in lots of markets, our technique now entails enhancing deal with choose international locations from our geographical presence, which guarantees excessive development potential,” Ajanta Pharma knowledgeable its shareholders.

These territories supply a big branded generics pharma market dimension, however the firm’s presence nonetheless stays small, it added.

“We plan to ramp up our presence in these markets and add worth to the sufferers’ decisions by our differentiated product portfolio,” the drug agency mentioned.

The corporate’s branded generics enterprise accounted for 73 per cent of its revenues in FY 2023, with Indian, remainder of Asia and Africa contributing 31 per cent, 26 per cent and 15 per cent, respectively.

Ajanta Pharma famous that as a way to obtain its targets, it has enhanced capital allocation to branded generics companies throughout India, the remainder of Asia and Africa. “Our strategic intent is mirrored in our efforts throughout FY 2023 to extend our product filings by thrice and improve crew dimension by 50 per cent in the remainder of Asia and Africa markets,” it acknowledged. The corporate will proceed to work on this strategy to realize development within the coming years, it added.

It additionally plans to boost the productiveness of current 4,500 plus subject groups unfold throughout India and remainder of the world markets by enabling them with extra digital instruments and serving to them get essentially the most out of the rising portfolio, the drug maker acknowledged. Ajanta Pharma posted a income of Rs 3,743 crore in FY23.